Navigation Links
TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
Date:12/10/2012

PHILADELPHIA, Dec. 10, 2012 /PRNewswire/ -- TransCelerate BioPharma Inc. ("TransCelerate") today announced that Dalvir Gill, PhD, has been appointed Chief Executive Officer, effective January 1, 2013. Dr. Gill will lead the independent non-profit entity, which was formed by ten healthcare and pharmaceutical companies in September to improve the quality of clinical studies and bring new medicines to patients faster by facilitating the collaboration required to solve common challenges encountered during the clinical trial process. Dr. Gill will succeed Garry Neil, MD, who has served as interim CEO of TransCelerate since the organization was formed in September. Dr. Neil will remain as Chairman of the Board of Directors for TransCelerate.

TransCelerate member organizations are currently working together on improving clinical study execution. Under this program, TransCelerate seeks to provide the following solutions for clinical trials: development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of risk-based site monitoring approach and standards, development of clinical data standards, and establishment of a comparator drug supply model.

"I am honored to lead this organization and work with the global research and development community to assess, refine and create processes to bring innovative new medicine to the public faster," said Dr. Gill.

Dr. Gill has more than 25 years of drug development experience. Prior to his appointment as CEO of TransCelerate, Dr. Gill was the President of Phase II-IV Drug Development at PharmaNet-i3, an organization specializing in drug development services. In this role, Dr. Gill was responsible for a global business spanning nearly 40 countries.

"Dr. Gill is a recognized industry leader with a proven history of success in the field of drug development. His deep experience across the pharmaceutical industry will help TransCelerate to advance key initiatives and provide solutions that will have measurable impact for patients worldwide," said Dr. Neil, Partner and Head of Pharmaceutical Research and Development at Apple Tree Partners.

Dr. Gill earned his BS in Applied Biology from the University of Hertfordshire and his PhD in Pathobiology from the Royal Free Hospital School of Medicine, University of London. He also holds a diploma in the health economics of pharmaceuticals from the executive program of the Stockholm School of Economics. Dr. Gill has presented his research and spoken at numerous conferences and has authored over 30 scientific publications. He also is an elected fellow of the Royal Society of Medicine.

About TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. is a non-profit organization established to simplify drug development challenges and accelerate the delivery of new medicines for patients by creating solutions to make clinical trial execution more efficient. The organization evolved from relationships fostered via the Hever Group, a forum for executive R&D leadership to discuss relevant issues facing the industry and solutions for addressing common challenges. Founding members include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group, and Sanofi, and all have representation on the Board of Directors. Membership in TransCelerate is open to all pharmaceutical and biotechnology companies who can contribute to and benefit from these shared solutions. TransCelerate's headquarters are located in Philadelphia, PA.

 

Media Contacts (Porter Novelli):

Virginia Amann

608.207.0082

Virginia.Amann@PorterNovelli.com

Shannon Caudill

740.281.3715 or 614.378.9042

Shannon.Caudill@PorterNovelli.com


'/>"/>
SOURCE TransCelerate BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
2. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
3. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. John A. Orwin Joins Array BioPharma Board Of Directors
6. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
8. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
9. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
10. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
11. PDL BioPharma Announces Conversion Rate Adjustments for Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  If only ... tumor had a mutation-conferring resistance to chemotherapy, thousands ... genomics research has focused on finding these mutations ... even from circulating tumor DNA in blood — ... oncology therapeutics. Unfortunately, however, detecting these ...
(Date:2/16/2017)... ... 2017 , ... Avomeen & MichBio will be hosting a BioMixer next week ... Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). BioMixers are a casual, ... interact with peers, make new connections and talk bio biz. , Cost:, ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., ... groundbreaking therapies to treat severe neurological disorders, today ... treated with AGT-181, the company,s investigational therapy for ... known as mucopolysaccharidosis type I, or MPS I). ... proof-of-concept (POC) study, presented today at the 13 ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
(Date:2/3/2017)... Biomedical Research Institute announced that its Board of Trustees has ... Institute,s new President and CEO. Dr. Schlesinger will take the ... currently the Chair of the Department of Microbial Infection and ... at Ohio State University. "We are delighted to ... Texas Biomed," said Dr. James O. Rubin , Board ...
(Date:2/2/2017)... Feb. 1, 2017  Central to its deep ... advances worldwide, The Japan Prize Foundation today announced ... have pushed the envelope in their respective fields ... Three scientists are being recognized with the 2017 ... not only contribute to the advancement of science ...
Breaking Biology News(10 mins):